Sonen Capital LLC Sells 4,865 Shares of Edwards Lifesciences Co. (NYSE:EW)

Sonen Capital LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 58.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,417 shares of the medical research company’s stock after selling 4,865 shares during the period. Sonen Capital LLC’s holdings in Edwards Lifesciences were worth $261,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Caprock Group LLC boosted its holdings in shares of Edwards Lifesciences by 4.8% in the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock valued at $597,000 after buying an additional 392 shares in the last quarter. Oak Thistle LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $700,000. Czech National Bank grew its holdings in Edwards Lifesciences by 48.1% in the third quarter. Czech National Bank now owns 106,252 shares of the medical research company’s stock worth $7,361,000 after purchasing an additional 34,487 shares during the last quarter. Asset Management One Co. Ltd. increased its position in shares of Edwards Lifesciences by 0.5% during the third quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company’s stock worth $22,393,000 after purchasing an additional 1,622 shares in the last quarter. Finally, Birch Hill Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 0.9% during the 3rd quarter. Birch Hill Investment Advisors LLC now owns 390,069 shares of the medical research company’s stock valued at $27,024,000 after purchasing an additional 3,542 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The disclosure for this sale can be found here. Over the last quarter, insiders sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.8 %

Shares of EW opened at $86.43 on Friday. The stock’s 50-day moving average price is $90.28 and its 200-day moving average price is $78.89. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.29 and a beta of 1.05. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. The business had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of several research analyst reports. Piper Sandler boosted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday. Mizuho upped their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $93.33.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.